Mission Therapeutics to participate in the 9th Annual Solebury Strategic Communications Private Company Showcase

CAMBRIDGE, UK – 11 October 2022 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), today announced that its CEO, Anker Lundemose, will attend and present at the 9th Annual Fall Private Company Showcase, co-hosted by Solebury Strategic Communications, BMO and Goodwin, on 13 October 2022 in New York.

Dr Lundemose will be available for one-to-one meetings and will discuss the Company’s business strategy, technology, discovery platform and development programmes in a 20-minute presentation at 11am EDT / 4pm BST.

As well as the company presentations from select private biotechs, the event’s agenda includes two thematic panels, one-to-one meetings with company executives, and a networking reception.

For individuals interested in attending the meeting, please contact the organisers for further information.

– ENDS –


Mission Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel: +44 (0)1223 607 340 
Instinctif Partners
Melanie Toyne-Sewell / Katie Duffell/ Jonjo Cordey
Tel: +44 (0) 20 7457 2013


About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong links with key academic and research centers, including Prof. Steve Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company also has secured major industry partnerships, including its collaboration with AbbVie in November 2018, for the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease. The Company is managed by a team with broad international, commercial and clinical-science experience.

To date the Company has received £73 million / $101 million in funding and its investors comprise blue chip institutional and corporate investors including: Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group and Rosetta Capital. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

For more information, please visit our website, www.missiontherapeutics.com, or follow us on Twitter or LinkedIn.